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Dear Editor,
Toxoplasma gondii is an intracellular parasite that has been 
associated with several mental disorders. It usually causes 
an inapparent primary infection. Found worldwide, T. 
gondii is capable of infecting virtually all warm-blooded 
animals.1-3
Schizophrenia is a neurological disorder characterized 
with long-term and devastating neuropsychological 
problems, usually presenting in adolescents or young 
adults. The disease affects almost 1.1% of the global 
population including all races and ethnic groups with an 
equal prevalence in both sexes.1 T. gondii seroprevalence 
is strongly associated with 12-month generalized anxiety 
disorder but not with other anxiety, depressive, or alcohol-
related disorders. Because of the intracellular nature of 
some parasites, their treatment and development of new 
drugs is a major challenge for scientists.4 Recently, the use 
of nanoparticles and nano-scaffolds has suggested for the 
treatment of parasitic diseases, although limited research 
has been done in this regard.5-7
Toxoplasma gondii modulates the secretion of 
neurotransmitters (such as dopamine) via producing 
tyrosine hydroxylase and interacting with astrocyte 
glial cells. Therefore, this parasite can be related to the 
pathogenesis of schizophrenia. The association between 
schizophrenia and toxoplasmosis requires researchers 
to investigate links between this parasitic infection with 
other neurological disorders such as paranoia, depression, 
and brain injuries. A higher probability of schizophrenia 
has been recorded in those who have antibodies against T. 
gondii in their sera. It has been suggested that T. gondii is 
translocated to target cerebral regions via dendritic cells 
and macrophages.1
The parasite cysts have been identified in astrocytes, 
indicating possible interactions between T. gondii cysts 
and these cells. In the brain tissue experimentally infected 
with virulent type I T. gondii, parasites were shown to be 
localized around neuronal nuclei of astrocytes. Therefore, 
research evidence suggests that T. gondii can play the role 
of a neuromodulator and infect neuronal cells within the 
brain.1
In fact, T. gondii cysts have been detected in various 
cerebral regions including basal ganglia, olfactory bulbs, 
hippocampus, thalamus, diencephalon, cortex, as well as 
in the amygdale, further highlighting the possible role 
of this parasite in brain damages.1 It has been suggested 
that T. gondii may use genes to augment its survival in 
its intermediate and definitive hosts. For reaching this 
goal, these genes may facilitate the translocation of the 
parasite to the brain to promote required behavioral 
modifications.1
The main aim of using nanoparticles/nano-scaffolds is 
to use them as a drug delivery system and to release the 
drug agent to affect the specific site. Recently, the use of 
particle systems such as nanomedicine has been advocated 
as a physical tool to improve the pharmacokinetic 
properties of various types of drug molecules in vivo.5-8
Another point supporting a link between schizophrenia 
and T. gondii is that both of these conditions can modulate 
the brain at early developmental stages. It has been noted 
that disorders such as schizophrenia, sclerosis, and 
Parkinson’s disease originate at early phases of the brain 
development. On the other hand, T. gondii is also able to 
infect the brain even in the perinatal period.1
A link has been proposed between T. gondii infection 
and the onset and progression of schizophrenia and other 
bipolar disorders. A study showed that T. gondii can 
infect the brain by creating cysts within its neurons and 
by producing tyrosine hydroxylase, an enzyme required 
for dopamine production.1
Dopamine regulates sleep cycle, motivation, attention, 
mood, and social activities. Also, a link between 
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dopamine and schizophrenia is well characterized, 
and all the drugs used to treat schizophrenia target this 
neurotransmitter. The levels of some neurotransmitters 
including dopamine (along with norepinephrine, etc) are 
affected in the patients infected with T. gondii as well; a 
process which is also known to be part of schizophrenia 
pathogenesis.1 Dopamine is important in regulating 
perceptional, behavioral, and other functional properties 
of the brain. Elevated levels of dopamine are related to the 
pathogenesis of a variety of neurological disorders such 
as schizophrenia and mania. For this reason, many drugs 
used to treat neuronal disorders target dopamine in part 
of their action.1
Multiple studies have been conducted in various 
populations to divulge the association between 
schizophrenia and T. gondii infection. Overall, these 
studies suggest a significant association between 
schizophrenia and toxoplasmosis, which can be the 
basis for opening a new path for treating psychiatric and 
neuronal diseases.1
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